Every May, the mental health sector posts. Tiles go purple. Stats get shared. And for a week, the conversation about young people's mental health gets louder. None of that is wrong. Awareness matters. But after more than a decade of awareness campaigns, it is worth asking a harder question: is awareness still the constraint? At one trust alone, over 6000 young people are currently waiting more than 52 weeks for CAMHS treatment. The bottleneck is not that people don't know mental health matters. It is that the system cannot treat them fast enough.
.png){kind=avatar}
.png)
Every May, the mental health sector posts. Tiles go purple. Stats get shared. And for a week, the conversation about young people's mental health gets louder.
None of that is wrong. Awareness matters. But after more than a decade of awareness campaigns, it is worth asking a harder question: is awareness still the constraint?
At one trust alone, over 6000 young people are currently waiting more than 52 weeks for CAMHS treatment.
The bottleneck is not that people don't know mental health matters. It is that the system cannot treat them fast enough.
For young people with anxiety, the standard treatment pathway is exposure-based CBT, typically delivered over 8-16 sessions within NHS Talking Therapies. The evidence for this approach is strong. But the delivery model has a structural problem.
Exposure work is the component of CBT that most directly drives recovery. It is also the component where patients are most likely to disengage. Imaginal exposure can feel too abstract, particularly for younger patients or those with neurodevelopmental differences. Real-world exposure can feel too overwhelming as a next step. And therapists are often left without a structured way to bridge that gap within the session itself.
The result is a pathway that works in theory but stalls in practice. Sessions accumulate. Progress plateaus. And the waiting list behind that patient grows longer.
Over the past 3 years, we have been working with NHS trusts, charities, and universities to develop a structured, in-session exposure rehearsal tool called Boundless. It uses immersive simulations that the therapist controls, allowing patients to practise engaging with anxiety-provoking situations at a graded pace, within the structure of a standard therapy session.
It is not a new type of therapy. It sits within existing Step 2 and Step 3 CBT pathways. Therapists do not need to retrain in a new clinical model. We provide CPD-accredited platform training so they are confident from day one. It runs on hardware services already own.
What it does is make the exposure component of therapy more accessible for patients who struggle with conventional approaches, and more efficient for the services delivering it.
An independent health economics evaluation conducted by CHEATA (Centre for Healthcare Equipment and Technology Adoption, Nottingham University Hospitals NHS Trust) modelled outcomes for a cohort of 100 GAD patients.
The findings, inclusive of license fees and based on an assumption of equivalent recovery achieved in fewer sessions:
Treatment reduced from 8-16 sessions to 3-4.
Over £21,000 saved per 100 patients from reduced session count and therapist time.
Net monetary benefit of over £1,700 per patient.
ICER of £211-£214 per QALY, well below NICE cost-effectiveness thresholds.
Separately, XRT's own clinical data from the last 100 patients to receive therapy with Boundless shows a 71% reliable recovery rate, compared to 49% with conventional talking therapies. These are two different data sources measuring different things, and we are careful not to conflate them.
The implications for young people's services are significant. CAMHS pathways face the same structural challenge as adult services, with an additional layer of complexity: many young people referred for anxiety also present with neurodevelopmental differences, particularly autism, where imaginal exposure is even less accessible.
Boundless was originally developed through research with autistic young people with specific phobias. The published evidence base (Maskey et al, 2014, 2019a, 2019b, 2019c) demonstrates that structured, visual, graded exposure can reach patients who would not otherwise engage with conventional approaches. This is not a theoretical application. It is where the tool began.
If a CAMHS service currently delivers 8-16 sessions per patient and can achieve equivalent outcomes in 3-4, the impact on waiting lists is not marginal. It is structural. The same clinical team, with the same resources, can see meaningfully more patients.
This week, awareness will be posted about. Shared. Liked. And that is fine.
But if you are a clinical lead, a service director, or a commissioner reading this, the question is not whether mental health matters. You already know it does. The question is whether your anxiety pathway is delivering the throughput your waiting list demands, and whether your therapists have the tools they need to make each session count.
Boundless is used by 7 NHS trusts, 3 charities, and 1 ICB across the UK. It is DTAC-certified, UKCA-marked, and typically deployed within 2-4 weeks.
If you want to talk about what this could look like in your service, contact hello@xrtherapeutics.co.uk.
